1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Coloplast A/S
  6. Summary
    COLO B   DK0060448595

COLOPLAST A/S

(COLO B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-07-05 am EDT
827.00 DKK   -0.36%
06/30Coloplast awarded AscenDrive Agreement for Ostomy Products with Premier, Inc.
GL
06/30Coloplast Wins AscenDrive Agreement for Ostomy Products with Premier, Inc
CI
05/17New informational website around larynx cancer surgery
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/29/2022 06/30/2022 07/01/2022 07/04/2022 07/05/2022 Date
813.4(c) 808.4(c) 826.6(c) 830(c) 827(c) Last
169 107 315 031 177 025 112 387 161 536 Volume
+0.10% -0.61% +2.25% +0.41% -0.36% Change
More quotes
Estimated financial data (e)
Sales 2022 22 136 M 3 048 M 3 048 M
Net income 2022 4 871 M 671 M 671 M
Net Debt 2022 17 661 M 2 432 M 2 432 M
P/E ratio 2022 35,9x
Yield 2022 2,16%
Sales 2023 24 499 M 3 373 M 3 373 M
Net income 2023 5 740 M 790 M 790 M
Net Debt 2023 16 795 M 2 313 M 2 313 M
P/E ratio 2023 30,6x
Yield 2023 2,44%
Capitalization 176 B 24 175 M 24 175 M
EV / Sales 2022 8,73x
EV / Sales 2023 7,85x
Nbr of Employees 14 286
Free-Float 57,1%
More Financials
Company
Coloplast A/S specializes in the design, manufacturing, and marketing of disposable medical products. Net sales break down by family of products as follows: - hygiene products (76.4%): urine bags, plugs, urinary testing systems and sets, etc.; - wound care and skincare products (12.8%): wound dressings, bandages, creams and gels ; - ostomy care products (10.8%): bags and equipment used following intestinal... 
More about the company
Ratings of Coloplast A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about COLOPLAST A/S
06/30Coloplast awarded AscenDrive Agreement for Ostomy Products with Premier, Inc.
GL
06/30Coloplast Wins AscenDrive Agreement for Ostomy Products with Premier, Inc
CI
05/17New informational website around larynx cancer surgery
GL
05/17New informational website around larynx cancer surgery
GL
05/11Announcement no. 06/2022 - Coloplast announces the successful issuance of EUR 2.2 billi..
GL
05/09Announcement no. 05/2022 - Coloplast announces the establishment of its Euro Medium Ter..
GL
05/09Announcement no. 05/2022 - Coloplast announces the establishment of its Euro Medium Ter..
GL
05/09COLOPLAST A/S : Ex-dividend day for interim dividend
FA
05/06S&P Assigns Stable Outlook To Danish Medical Technology Group Coloplast
MT
05/05GLOBAL MARKETS LIVE : BAE, Shell, Berkshire Hathaway, Nissan, Shopify...
05/05The Board of Directors of Coloplast A/S Approves A Half Year Interim Dividend of DKK 5 ..
CI
05/05TRANSCRIPT : Coloplast A/S, H1 2022 Earnings Call, May 05, 2022
CI
05/05Coloplast Shares Down as Fiscal H1 Profit Slips; Revenue Grows
MT
05/05Coloplast delivers a solid Q2 with 7% organic growth and a 31% EBIT margin and revises ..
GL
05/05Coloplast delivers a solid Q2 with 7% organic growth and a 31% EBIT margin and revises ..
GL
More news
News in other languages on COLOPLAST A/S
06/30Coloplast obtient un accord AscenDrive pour les produits de stomie avec Premier, Inc.
06/29ÍNDICES : Cathie le da a Warren un uppercut
06/27INDICES : Cathie décoche un uppercut à Warren
06/27BOLSA DE MADRID : La Reserva Federal juega en exceso, y funciona
06/27La Fed surjoue, et ça fonctionne
More news
Analyst Recommendations on COLOPLAST A/S
More recommendations
Chart COLOPLAST A/S
Duration : Period :
Coloplast A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COLOPLAST A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 827,00 DKK
Average target price 1 038,93 DKK
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Kristian Villumsen President & Chief Executive Officer
Anders Lonning-Skovgaard Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Allan Rasmussen Executive Vice President-Global Operations
Jette Nygaard-Andersen Independent Director